Table 5.
Year | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
---|---|---|---|---|---|---|
Nonacute PCI | 13,517 | 14,550 | 15,253 | 14,454 | 14,225 | 14,255 |
Mortality PCI non-acute overall (%) |
14 (0.10) |
15 (0.10) |
25 (0.16) |
13 (0.09) |
26 (0.18) |
23 (0.16) |
Myocardial infarction as complication | 83 | 78 | 80 | 107 | 174 | 101 |
With new Q‑wave | 22 | 11 | 8 | 13 | 15 | 5 |
Defined by troponin or CK | 58 | 66 | 55 | 79 | 132 | 93 |
Nonfemoral (radial) approach | 3084 | 4260 | 5834 | 5817 | 5580 | 6868 |
Switch to femoral during procedure | – | – | – | 256 | 366 | 551 |
Local radial artery complications | – | – | – | – | – | 33 |
Reversible neurologic complications | 19 | 14 | 17 | 7 | 11 | 24 |
Irreversible neurologic complications | 4 | 4 | 2 | 1 | 1 | 6 |
Vascular peripheral complication | 110 | 123 | 105 | 95 | 225 | 108 |
With surgery or transfusion | 17 | 32 | 18 | 15 | 25 | 23 |
With local injection of thrombin | 24 | 32 | 25 | 23 | 55 | 31 |
Adverse reactions to contrast media | 27 | 29 | 30 | 24 | 30 | – |
Austrian Questionnaire “Non-acute percutaneous coronary interventions PCI” [11]
cases; n pooled analysis
Striking differences in italics
“–” data not available
PCI percutaneous coronary intervention, CK Creatine (Phospho)Kinase